NasdaqGM - Nasdaq Real Time Price USD
Kalaris Therapeutics, Inc. (KLRS)
5.41
-0.42
(-7.20%)
At close: May 5 at 4:00:01 PM EDT
5.90
+0.49
+(9.06%)
Pre-Market: 5:12:00 AM EDT
Breakdown
12/31/2023
12/31/2022
Total Assets
3,333
3,899
Total Liabilities Net Minority Interest
48,350
34,171
Total Equity Gross Minority Interest
-45,017
-30,272
Total Capitalization
-45,017
-27,019
Common Stock Equity
-45,017
-30,272
Net Tangible Assets
-45,017
-30,272
Working Capital
-609
-1,792
Invested Capital
-45,017
-27,019
Tangible Book Value
-45,017
-30,272
Total Debt
--
3,253
Net Debt
--
194
12/31/2022 - 7/30/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BSLN.SW Basilea Pharmaceutica AG
44.30
+0.57%
DNTH Dianthus Therapeutics, Inc.
21.55
-0.69%
328.SG MeiraGTx Holdings PLC
5.55
-11.90%
BT3.BE Lineage Cell Therapeutics Inc
0.3940
-5.74%
25I.SG ImmuPharma PLC
0.0320
+12.28%
GNFTF Genfit S.A.
3.5400
0.00%
CLDWW Calidi Biotherapeutics, Inc.
0.0055
-15.38%
22Z.SG Zealand Pharma A/S
64.02
-1.30%
NBTX Nanobiotix S.A.
3.5400
+2.61%
PI3.DU Gubra AS
54.30
+0.84%